INOVIQ Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Leearne Hinch
Algemeen directeur
AU$609.3k
Totale compensatie
| Percentage CEO-salaris | 68.0% |
| Dienstverband CEO | 8yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3.2yrs |
| Gemiddelde ambtstermijn bestuur | 4.9yrs |
Recente managementupdates
Recent updates
We Think INOVIQ (ASX:IIQ) Can Afford To Drive Business Growth
Apr 22
A Look At The Intrinsic Value Of INOVIQ Ltd (ASX:IIQ)
Mar 01We Think Shareholders May Want To Consider A Review Of INOVIQ Ltd's (ASX:IIQ) CEO Compensation Package
Nov 22Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Jun 21Companies Like INOVIQ (ASX:IIQ) Are In A Position To Invest In Growth
Feb 16INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans
Sep 28We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely
Jun 08We're Keeping An Eye On INOVIQ's (ASX:IIQ) Cash Burn Rate
Jan 28Are Insiders Selling BARD1 Life Sciences Limited (ASX:BD1) Stock?
Mar 02Don't Ignore The Fact That This Insider Just Sold Some Shares In BARD1 Life Sciences Limited (ASX:BD1)
Mar 02BARD1 Life Sciences (ASX:BD1) Is In A Good Position To Deliver On Growth Plans
Dec 28Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | AU$609k | AU$414k | -AU$7m |
| Mar 31 2024 | n/a | n/a | -AU$7m |
| Dec 31 2023 | n/a | n/a | -AU$7m |
| Sep 30 2023 | n/a | n/a | -AU$8m |
| Jun 30 2023 | AU$558k | AU$396k | -AU$9m |
| Mar 31 2023 | n/a | n/a | -AU$15m |
| Dec 31 2022 | n/a | n/a | -AU$21m |
| Sep 30 2022 | n/a | n/a | -AU$20m |
| Jun 30 2022 | AU$485k | AU$376k | -AU$18m |
| Mar 31 2022 | n/a | n/a | -AU$14m |
| Dec 31 2021 | n/a | n/a | -AU$11m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$867k | AU$330k | -AU$11m |
| Mar 31 2021 | n/a | n/a | -AU$8m |
| Dec 31 2020 | n/a | n/a | -AU$5m |
| Sep 30 2020 | n/a | n/a | -AU$4m |
| Jun 30 2020 | AU$712k | AU$330k | -AU$3m |
| Mar 31 2020 | n/a | n/a | -AU$3m |
| Dec 31 2019 | n/a | n/a | -AU$2m |
| Sep 30 2019 | n/a | n/a | -AU$2m |
| Jun 30 2019 | AU$442k | AU$361k | -AU$2m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$403k | AU$359k | -AU$2m |
Compensatie versus markt: De totale vergoeding ($USD 395.97K ) Leearne } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Australian markt ($USD 297.98K ).
Compensatie versus inkomsten: De vergoeding van Leearne is gestegen terwijl het bedrijf verliesgevend is.
CEO
Leearne Hinch
8yrs
Tenure
AU$609,311
Compensatie
Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of INOVIQ Ltd (formerly known as BARD1 Life Sciences Limited) since November 7, 2016. Dr. Hinch is a biotech...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chief Executive Officer | 8yrs | AU$609.31k | 0.25% A$ 119.3k | |
| CFO & Company Secretary | 2yrs | AU$322.87k | 0.036% A$ 17.4k | |
| Chief Scientific Officer | 3.2yrs | AU$350.25k | 0.054% A$ 26.1k |
3.2yrs
Gemiddelde duur
Ervaren management: Het managementteam van IIQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Non-Executive Director | 5.4yrs | AU$62.90k | 0.48% A$ 232.6k | |
| Non-Executive Chairman | less than a year | AU$729.81k | 4.64% A$ 2.3m | |
| Independent Non-Executive Director | 4.3yrs | AU$74.93k | 0.21% A$ 103.3k | |
| Independent Non-Executive Director | 5.4yrs | AU$62.90k | 0.54% A$ 262.9k | |
| Member of Advisory Board | 7.3yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
4.9yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van IIQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).